miércoles, 28 de enero de 2009

2009 PATENTES: Annus horribilis...









Mas de 100 patentes expiraran a lo largo de 2009. Entre ellas se incluyen 13 grandes productos. Las compañias más afectadas serán GlaxoSmithKline y Pfizer seguidas de Novartis y Takeda.

En el 2008 fueron
Merck & Co's Fosamax (alendronate), Pfizer's Camptosar (irinotecan) and Wyeth's Effexor XR (venlafaxine).


Según previsiones de Global Insight:

...a number of distinctive trends began to emerge last year in the patent challenge arena.
  • First was the relative confidence among generics makers to challenge much earlier in the patent lifecycle than was previously the case.
  • Second was their focus on niche therapeutic areas with restricted high-margin product markets - generics giants including Teva Pharma, Ranbaxy, Stada and Mylan were actively pursuing this trend.
  • And third was Big Pharma’s willingness to accept settlements with generis makers again much earlier in the patent lawsuit period.
Mas...

No hay comentarios: